TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00162656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: half cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: half cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: without COPADM3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: without COPADM3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mini CYVE, without 3 maintenance courses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMB B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMB C
Study: NCT01287689

Intervention type: OTHER
Intervention: Immunoglobulin G (IgG)
Description: Not applicable. All interventions are at the discretion of the investigator. All marketed IgG formulations can be documented.
Study: NCT00553644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT01402492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine + Naltrexone
Description: Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine + Naltrexone
Description: Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Naltrexone
Description: Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
Study: NCT01980992

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Wheat OIT
Description: Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wheat OIT
Description: Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
Study: NCT00068497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study: NCT03453710

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bankart Repair plus Remplissage
Description: Arthroscopic Bankart repair with a minimum of 3 anchors~1 or 2 anchor Remplissage subsequently performed with percutaneous anchor insertion in the base of the Hill-Sachs defect, and sutures passed in a horizontal mattress configuration 1 cm apart, tied in the subacromial space.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Latarjet coracoid transfer
Description: Coracoid transfer performed via deltopectoral approach with horizontal subscapularis split. Graft placed in the conventional orientation, secured with 2 screws, ensuring the graft is not lateral to the glenoid rim.
Study: NCT02966249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmetomidine intravenously
Description: Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously 10 min before spinal anesthesia in total knee arthroplasty

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmetomidine intravenously
Description: Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously 10 min before spinal anesthesia in total knee arthroplasty

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline added intrathecally
Description: Normal Saline added to 5μgr dexmetomidine up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline added intrathecally
Description: Normal Saline added to 5μgr dexmetomidine up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
Study: NCT00409448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselor-assisted problem solving (CAPS)
Description: In CAPS, a trained counselor will guide families through a 6-month structured online problem-solving and skill-building program via one-on-one videoconference sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-resource comparison (IRC)
Description: Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources, but not the CAPS website content.
Study: NCT00741286

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Asprin (100mg) plus placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol
Description: Aspirin (100mg) plus cilostazol (200mg)
Study: NCT02634359

Intervention type: DEVICE
Group type: OTHER
Intervention: EarlySense home device
Description: Passive contact-free monitoring at home measuring HR, RR and movements Arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF

Intervention type: DEVICE
Group type: OTHER
Intervention: EarlySense home device
Description: Passive contact-free monitoring at home measuring HR, RR and movements Arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF

Intervention type: DEVICE
Group type: OTHER
Intervention: EarlySense home device
Description: Passive contact-free monitoring at home measuring HR, RR and movements Arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vaginal ultrasound
Description: Vaginal ultrasound for the purpose of determining follicle size Arms:IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vaginal ultrasound
Description: Vaginal ultrasound for the purpose of determining follicle size Arms:IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vaginal ultrasound
Description: Vaginal ultrasound for the purpose of determining follicle size Arms:IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Test
Description: Hormonal profile blood tests arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
Study: NCT02966249

Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline intrathecally
Description: 0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty

Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline intrathecally
Description: 0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate solution intravenously
Description: Continuous infusion of Ringer's Lactate solution given intravenously, starting 10 minutes before spinal anesthesia up to the end of the operation

Intervention type: DRUG
Group type: OTHER
Intervention: Ringer's Lactate solution intravenously
Description: Continuous infusion of Ringer's Lactate solution given intravenously, starting 10 minutes before spinal anesthesia up to the end of the operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmetomidine intrathecally
Description: 5 μgr dexmetomidine given intrathecally once for anesthesia in total knee replacement

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmetomidine intrathecally
Description: 5 μgr dexmetomidine given intrathecally once for anesthesia in total knee replacement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmetomidine intrathecally
Description: 5 μgr dexmetomidine given intrathecally once for anesthesia in total knee replacement
Study: NCT04870398

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vital Pulp therapy-Partial pulpotomy
Description: Removal of inflamed pulp tissue, hemostasis and placement of pulpotomy material

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vital Pulp therapy-Partial pulpotomy
Description: Removal of inflamed pulp tissue, hemostasis and placement of pulpotomy material
Study: NCT02313350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis with Discogel
Description: Discogel® is provided in a kit containing a 2 ml solution for injection with two disposable 1ml syringes, each for single use which is stored at room temperature. Discogel® chemonucleolysis for herniated disc-related sciatica is performed under local anesthesia .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open discectomy
Description: The comparator is open surgical discectomy. The procedure will be performed under general anesthesia. It will consist in removing the disc herniation after exposition and examination of the nerve root.
Study: NCT02300467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV120401
Description: 5 to 45 mg/day PO for 5 consecutive days and 2 days off
Study: NCT02063659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: Telotristat etiprate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching telotristat etiprate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching telotristat etiprate tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching telotristat etiprate tablets
Study: NCT01532999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: MBSR is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Present Centered Group Therapy
Description: The comparison control group will be PCGT, which was initially developed for use as a control group in a VA multi-site study that tested the effects of Trauma-Focused Group Therapy. Correspondingly, PCGT serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
Study: NCT02454439

Intervention type: OTHER
Group type: OTHER
Intervention: CRT implantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRT implantation
Study: NCT00803400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.~Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam + Aerobic exercise
Description: The patients assigned to exercise have to pass an ergometric test to determine their functional capacity expressed in METs for future exercise indication.~Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.~Then they follow a protocolized aerobic exercise plan for this study during 12 weeks.~The type of selected exercise consists of a rapid walk for 30 minutes divided in stages.~After each stage the patient has to control his own heart frequency that has to be between 50 and 75% of their maximum to assure an aerobic condition (American Cardiological Association).
Study: NCT02178254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin tromethamine
Description: A phosphonic acid derivative is the mono-acid salt of Fosfomycin with Tromethamine. Sequence 1-3 receive 3 grams oral sachet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin tromethamine
Description: A phosphonic acid derivative is the mono-acid salt of Fosfomycin with Tromethamine. Sequence 1-3 receive 3 grams oral sachet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin tromethamine
Description: A phosphonic acid derivative is the mono-acid salt of Fosfomycin with Tromethamine. Sequence 1-3 receive 3 grams oral sachet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin disodium
Description: ZTI-01 is a phosphonic acid derivative formulated as a disodium salt intravenous formulation. ZTI-01 acts by inhibiting peptidoglycan assembly, thereby disrupting cell wall synthesis. Sequence 1-3 receive 1 gram and 8 grams of Intravenous ZTI-01 for 1-hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin disodium
Description: ZTI-01 is a phosphonic acid derivative formulated as a disodium salt intravenous formulation. ZTI-01 acts by inhibiting peptidoglycan assembly, thereby disrupting cell wall synthesis. Sequence 1-3 receive 1 gram and 8 grams of Intravenous ZTI-01 for 1-hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin disodium
Description: ZTI-01 is a phosphonic acid derivative formulated as a disodium salt intravenous formulation. ZTI-01 acts by inhibiting peptidoglycan assembly, thereby disrupting cell wall synthesis. Sequence 1-3 receive 1 gram and 8 grams of Intravenous ZTI-01 for 1-hour infusion
Study: NCT03065621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Each cycle will be 28 days. Patient will take study drug daily during 21 days and then have a rest period of 7 days.
Study: NCT04574414

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychological testing and MRI imaging
Description: Every child will have three sessions with psychologists and be diagnosed as having or not having ADHD.~Every child will be invited to Krakow to undergo MRI measurements, including resting-state and event-related functional MRI, Diffusion Tensor Imaging (DTI), and T1/T2 structural MRI.

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychological testing and MRI imaging
Description: Every child will have three sessions with psychologists and be diagnosed as having or not having ADHD.~Every child will be invited to Krakow to undergo MRI measurements, including resting-state and event-related functional MRI, Diffusion Tensor Imaging (DTI), and T1/T2 structural MRI.
Study: NCT01425359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ranolazine placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine placebo
Study: NCT01631747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention Group
Description: Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet \& activity and use of pedometer

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
Study: NCT04452435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C21
Description: C21

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01984463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients will receive an epidural bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Patients will receive an epidural bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
Study: NCT04202224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg and Acetaminophen 500 mg
Description: Analgesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: Placebo.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No drug
Description: Standard surgical procedure without any preoperative medication.
Study: NCT03172325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 40 mg Adalimumab every other week is administered subcutaneously to all the patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 15 mg Methotrexate is weekly administered to all the patients.
Study: NCT05299281

Intervention type: DEVICE
Group type: OTHER
Intervention: Micropulse transscleral cyclophotocoagulation (MP-TSCPC)
Description: patients undergone micropulse laser transscleral cyclophotocoagulation. The laser settings ranged from 2000- 2500 mW of 810 nm infrared diode laser radiation set on micro- pulse mode (Iris Medical Instruments, Mountain View, CA, USA), delivered over 100-200 s (envelope of micropulses) depending on severity of the case and other patient factors.~Follow-up was done at day 1, week 1, month 1, month 3, and month 6 postoperatively.
Study: NCT03107936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smokeSCREEN game
Description: smokeSCREEN is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
Study: NCT04201860

Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial blood gas analyses and haemostasis measures
Description: Under aseptic conditions, a puncture of radial artery was performed: three mL of the arterial blood sample were used for the haemostasis measure, while one mL was tested for the blood gases analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial blood gas analyses and haemostasis measures
Description: Under aseptic conditions, a puncture of radial artery was performed: three mL of the arterial blood sample were used for the haemostasis measure, while one mL was tested for the blood gases analysis.
Study: NCT04042337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment
Description: PRT will target functional communication abilities
Study: NCT04341389

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)
Description: Intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study: NCT02756689

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient cervical ripening
Description: Subjects will undergo cervical ripening in the inpatient setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient cervical ripening
Description: Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
Study: NCT03402386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6548
Description: Oral tablet
Study: NCT01996982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CCS Device
Description: Core Cooling System Device
Study: NCT00859768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: The patient receives the SIPP at two different time points during their RT period. The first time point is before the first consultation with the radiotherapist (before starting RT) and the second time point is before the last consultation with the radiotherapist at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: The patient receives the SIPP at two different time points during their RT period. The first time point is before the first consultation with the radiotherapist (before starting RT) and the second time point is before the last consultation with the radiotherapist at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care.